Eternygen Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • Series A2

  • Latest Deal Amount
  • $5.88M

  • Investors
  • 4

Eternygen General Information

Description

Developer of a novel therapy intended to offer treatment for metabolic diseases. The company's therapy offers small molecule inhibitors for the treatment of diet-related metabolic diseases, addressing the sodium-coupled citrate transporter which is a key regulator of lipid metabolism involved in the pathogenesis of fatty liver, diabetes, and obesity, enabling doctors to offer a safe and effective drug for the treatment of these widespread diseases via targeted adjustment of underlying metabolic failure.

Contact Information

Website
www.eternygen.de
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Karl-Liebknecht Straße 34
  • 10178 Berlin
  • Germany
+49 030
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • Karl-Liebknecht Straße 34
  • 10178 Berlin
  • Germany
+49 030

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Eternygen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series A2) 26-Oct-2020 $5.88M Completed Pre-Clinical Trials
3. Accelerator/Incubator 01-Apr-2020 Completed Startup
2. Later Stage VC (Series A) 09-Jan-2017 $8.39M $8.39M Completed Startup
1. Seed Round 01-Oct-2012 Completed Startup
To view Eternygen’s complete valuation and funding history, request access »

Eternygen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a novel therapy intended to offer treatment for metabolic diseases. The company's therapy offers small mole
Drug Discovery
Berlin, Germany
7 As of 2023

Amsterdam, Netherlands
 

Shenzhen, China
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Eternygen Competitors (20)

One of Eternygen’s 20 competitors is NorthSea Therapeutics, a Venture Capital-Backed company based in Amsterdam, Netherlands.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NorthSea Therapeutics Venture Capital-Backed Amsterdam, Netherlands
HighTide Therapeutics Formerly VC-backed Shenzhen, China
Akero Therapeutics Corporate Backed or Acquired South San Francisco, CA
NGM Biopharmaceuticals Private Equity-Backed South San Francisco, CA
Madrigal Pharmaceuticals Formerly VC-backed West Conshohocken, PA
You’re viewing 5 of 20 competitors. Get the full list »

Eternygen Patents

  • 16

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • Pending

  • Expiring in next 12 mo

Eternygen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4370519-A1 5,6,7,8-tetrahydro-2,6- and 2,7-naphthyridine derivatives for use in the treatment of diseases responsive to citrate transporter modulation Inactive 14-Jul-2021
WO-2023285583-A1 5,6,7,8-tetrahydro-2,6- and 2,7-naphthyridine derivatives for use in the treatment of diseases responsive to citrate transporter modulation Inactive 14-Jul-2021
GB-201704357-D0 Inhibitor of citrate transporter Inactive 20-Mar-2017
GB-2560713-A Inhibitor of citrate transporter Inactive 20-Mar-2017
US-20200087258-A1 Inhibitor of citrate transporter and their use in therapy Inactive 20-Mar-2017 A61K31/397
To view Eternygen’s complete patent history, request access »

Eternygen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Eternygen Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
German Accelerator Accelerator/Incubator
Epidarex Capital Venture Capital Minority
Evotec Corporation Minority
IBB Ventures Venture Capital Minority
To view Eternygen’s complete investors history, request access »

Ready to get started?

Request a free trial

Eternygen FAQs

  • When was Eternygen founded?

    Eternygen was founded in 2012.

  • Where is Eternygen headquartered?

    Eternygen is headquartered in Berlin, Germany.

  • What is the size of Eternygen?

    Eternygen has 7 total employees.

  • What industry is Eternygen in?

    Eternygen’s primary industry is Drug Discovery.

  • Is Eternygen a private or public company?

    Eternygen is a Private company.

  • What is Eternygen’s current revenue?

    The current revenue for Eternygen is .

  • How much funding has Eternygen raised over time?

    Eternygen has raised $14.3M.

  • Who are Eternygen’s investors?

    German Accelerator, Epidarex Capital, Evotec, and IBB Ventures have invested in Eternygen.

  • Who are Eternygen’s competitors?

    NorthSea Therapeutics, HighTide Therapeutics, Akero Therapeutics, NGM Biopharmaceuticals, and Madrigal Pharmaceuticals are some of the 20 competitors of Eternygen.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process